Mutations in the glucosylceramidase beta (GBA) gene are strongly associated with neurodegenerative diseases marked by protein aggregation. GBA encodes the lysosomal enzyme glucocerebrosidase, which breaks down glucosylceramide. A common explanation for the link between GBA mutations and protein aggregation is that lysosomal accumulation of glucosylceramide causes impaired autophagy. We tested this hypothesis directly by measuring protein turnover and abundance in Drosophila mutants with deletions in the GBA ortholog Gba1b. Proteomic analyses revealed that known autophagy substrates, which had severely impaired turnover in autophagy-deficient Atg7 mutants, showed little to no overall slowing of turnover or increase in abundance in Gba1b mutants. Likewise, Gba1b mutants did not have the marked impairment of mitochondrial protein turnover seen in mitophagydeficient parkin mutants. Proteasome activity, microautophagy, and endocytic degradation also appeared unaffected in Gba1b mutants. However, we found striking changes in the turnover and abundance of proteins associated with extracellular vesicles (EVs), which have been proposed as vehicles for the spread of protein aggregates in neurodegenerative disease. These changes were specific to Gba1b mutants and did not represent an acceleration of normal aging. Western blotting of isolated EVs confirmed the increased abundance of EV proteins in Gba1b mutants, and nanoparticle tracking analysis revealed that Gba1b mutants had six times as many EVs as controls. Genetic perturbations of EV production in Gba1b mutants suppressed protein aggregation, demonstrating that the increase in EV abundance contributed to the accumulation of protein aggregates. Together, our findings indicate that glucocerebrosidase deficiency causes pathogenic changes in EV metabolism and may promote the spread of protein aggregates through extracellular vesicles.
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Introduction
Mutations in the gene encoding the lysosomal enzyme glucocerebrosidase, glucosylceramidase beta (GBA), are associated with neurodegeneration and brain protein aggregation [1, 2] . Homozygous mutations in GBA cause the lysosomal storage disorder Gaucher disease, which in some cases includes devastating neurological symptoms [3] , while heterozygous GBA mutations are the strongest risk factor for both Parkinson disease (PD) and the related disorder dementia with Lewy bodies [1, 2, 4] . Up to 10% of individuals with nonfamilial PD carry a GBA mutation [5] . In addition, PD patients with a GBA mutation have faster progression of both motor and cognitive symptoms [6] . To study the mechanisms underlying the association between GBA mutations and neurodegeneration, we created a Drosophila model of glucocerebrosidase (GCase) deficiency. Drosophila has two GBA homologs, designated Gba1a and Gba1b. The Gba1a gene is expressed exclusively in the midgut [7] , and deletion of this gene does not appear to confer deleterious phenotypes [8] . By contrast, the Gba1b gene is ubiquitously expressed [7] , and Gba1b deletion causes marked abnormalities. We previously reported that Gba1b null mutants exhibit phenotypes including shortened lifespan, locomotor and memory deficits, neurodegeneration, accumulation of the autophagy adaptor Ref(2)P (p62/ SQSTM1), and accumulation of ubiquitinated protein aggregates [9] . Similar phenotypes were subsequently seen in an independently generated Gba1b null mutant [8] .
The protein aggregation and elevated Ref (2) P levels in Gba1b mutants suggested that they had impaired autophagy, as did morphological changes in the autolysosomal system noted by Kinghorn et al. [8, 9] . These findings are consistent with previous reports of autolysosomal impairment upon loss of GCase activity [1, [10] [11] [12] [13] [14] [15] . Based on such findings, we and others hypothesized that lysosomal accumulation of glucosylceramide, the normal substrate of GCase, leads to impairment of autophagy [12, [16] [17] [18] . However, none of the work implicating autophagy in the pathogenic effects of GCase deficiency has yet established that GCase loss of function causes global impairment of autophagic degradation.
To investigate the autophagy failure model of GBA pathogenesis, we used proteomics-based techniques to measure protein turnover and abundance in Gba1b mutants and controls, as well as in flies with mutations in key autophagy (Atg7) or mitophagy (parkin) genes [19, 20] .
While Atg7 mutants showed marked and widespread slowing of autophagy substrate turnover, Gba1b mutants did not. The effects of Gba1b mutation on the turnover and abundance of autophagy substrates also failed to correlate with those of Atg7 or parkin mutations. Moreover, we detected no deficits in turnover mediated by the proteasome, microautophagy, or endocytosis. However, we found high incidences of faster turnover and increased abundance among proteins associated with extracellular vesicles (EVs), which have been previously suggested as a mechanism for the spread of protein aggregates in neurodegenerative disease. Biochemical studies confirmed increased abundance of EV marker proteins in isolated EVs from Gba1b mutants, and nanoparticle tracking analysis showed that the mutants had markedly increased numbers of EVs. Genetic manipulations to reduce EV production decreased the accumulation of ubiquitinated protein aggregates and Ref (2) P in Gba1b mutants, supporting the model that excessive EV abundance promotes the accumulation of protein aggregates. Together, our findings suggest that the most important pathological consequence of Gba1b loss of function is not failure of autophagic protein degradation but excessive production of extracellular vesicles.
Results

Gba1b mutations do not cause global impairment of autophagic protein degradation
To test the hypothesis that GCase deficiency causes impaired autophagic turnover, we compared protein degradation rates in heads from Gba1b mutants and controls using stable isotope labeling. In brief, our method involves feeding flies a stable heavy isotope of leucine and then using mass spectrometry to monitor the rate at which unlabeled proteins are degraded and replaced with labeled proteins [21] . We measured the influence of Gba1b loss of function on all proteins with data that met quality standards in both Gba1b mutants and controls (1297 proteins for turnover analysis, 4221 for abundance; S1 Data). We analyzed turnover data with Topograph [22] , software specifically designed for measurement of protein turnover via stable isotope labeling. We also compared protein abundance in Gba1b and control flies using Skyline [23] and MSstats [24] . Fold change in turnover and fold change in abundance were then calculated for every protein. Fold change for a protein was calculated as the value in Gba1b mutants divided by the value in controls.
We predicted that autophagy substrates would show slower turnover (longer half-lives) in Gba1b mutants, and that they might show increased abundance if synthesis did not decrease to match the slower degradation rate (Fig 1A) . We defined autophagy substrates as proteins from mitochondria, cytosolic ribosomes, endoplasmic reticulum (ER), and peroxisomes, all previously identified as targets of autophagy [25] [26] [27] [28] [29] [30] . We validated our prediction using turnover and abundance data from autophagy-deficient Atg7 mutants, which we characterized in previous work [21] (S1 Data). We first plotted Atg7 fold change in turnover against fold change in abundance for autophagy substrates to observe the overall pattern of proteostasis changes ( Fig  1B) . Atg7 mutants showed changes consistent with our prediction: the vast majority of autophagy substrates (72%) had slower turnover (fold change in half-life >1) and increased or unchanged abundance. We therefore used Atg7 mutant data as a reference for the effects of autophagy impairment. When we plotted fold change in turnover against fold change in abundance for Gba1b mutants, the pattern of changes was markedly different; only 15% of autophagy substrate proteins had slower turnover and increased or unchanged abundance ( Fig 1C) . Proteostasis of autophagy substrates in Gba1b mutants thus did not overall resemble the pattern seen in Atg7 mutants.
To compare in more detail the effects of Gba1b and Atg7 mutations on protein turnover and abundance, we performed several additional analyses, beginning by calculating Gba1b and Atg7 mean fold change in turnover (half-life) for the autophagy substrate proteins mentioned above. Each mutant was compared to its own control. Turnover of proteins from all three classes of autophagy substrates was significantly slowed in Atg7 mutants (p < 0.001 by nested ANOVA), but in Gba1b mutants there was no overall change in the half-lives of ribosomal or ER/peroxisomal proteins (Fig 1D; p = NS by nested ANOVA) and only a very mild slowing of mean mitochondrial protein turnover (mean fold change 1.15 ± 0.32; p = 0.02 by nested ANOVA; Fig 1D) .
To test further for evidence of impaired autophagy in Gba1b mutants, we compared the effects of Atg7 and Gba1b mutations on individual proteins. We began with turnover, plotting . Fold change (FC) in half-life vs. fold change in abundance for proteins from known organellar targets of autophagy (mitochondria, cytosolic ribosomes, endoplasmic reticulum (ER), and peroxisomes; n = 295). As predicted, the vast majority of these proteins (72%) have slower turnover and either increased or unchanged abundance (highlighted quadrant). Fold change = mutant half-life or abundance value divided by corresponding control value. (C) Turnover change vs. abundance change in heads from Drosophila Gba1b mutants. Only 15% of autophagy substrate proteins match the autophagy mutant pattern of slower turnover and increased or unchanged abundance. (D) Autophagy substrate proteins have dramatically slower mean turnover in Atg7 mutants, but not in Gba1b mutants. Box plot shows fold change in half-life (box: median and quartiles; whiskers: maximum and minimum values). Half-lives of mitochondrial, ribosomal, and ER/peroxisomal proteins (n = 186, 53, and 32 respectively) were significantly longer in Atg7 mutants compared to controls ( Ã p < 0.001 by nested ANOVA). ER and peroxisomes were combined for analysis due to the low numbers of peroxisomal proteins detected. In Gba1b mutants, only mitochondrial proteins (n = 258) had significantly slower mean turnover compared to controls ( # p = 0.02 by nested ANOVA; n = 63 ribosomal proteins and 51 ER/peroxisomal proteins).
https://doi.org/10.1371/journal.pgen.1007694.g001 the fold change in half-life for Gba1b mutants (Gba1b mutant half-life/Gba1b control half-life) against the fold change for Atg7 mutants (Atg7 mutant/Atg7 control). We compared Gba1b and Atg7 effects on individual proteins from each of the three autophagy substrate categories. There was no statistically significant relationship between the effects of Gba1b and those of autophagy ablation for mitochondrial, ribosomal, or ER/peroxisomal proteins (Fig 2A-2C) . We also tested for a relationship between Gba1b and Atg7 effects on protein abundance (Fig  2D-2F ) and found no significant correlation for any of the three autophagy substrate groups. The effects of Gba1b loss of function on protein turnover and abundance thus do not resemble the effects of autophagy ablation, and we find no evidence that Gba1b mutation causes global impairment of autophagic protein degradation.
Gba1b mutations do not cause impairment of mitophagy
One reported consequence of GBA loss of function is accumulation of dysfunctional mitochondria due to defective mitophagy [31, 32] ; the slight but statistically significant slowdown of mitochondrial protein turnover in Gba1b mutants therefore raised the possibility of a mild mitophagy deficit. We had previously found a mitochondrial protein turnover deficit in flies with mutations in the mitophagy factor parkin [21] , and we now compared the effects of Gba1b mutation on mitochondrial proteostasis with those of parkin. In parkin mutants, turnover was slowed for the vast majority of mitochondrial proteins (Fig 3A) . In Gba1b mutants, changes in mitochondrial protein turnover were both milder and less consistent (Fig 3A, S1  Data) . We considered the possibility that Gba1b mutants had a mitophagy defect that was obscured by compensatory upregulation of other mitochondrial protein turnover mechanisms, as we previously found in PINK1 B9 mutants, which lack a mitophagy factor upstream of Parkin [21] . In PINK1 B9 mutants, while the mean fold change in mitochondrial protein halflife was not significantly altered, the effects of PINK1 B9 mutation on individual proteins correlated strongly with those of parkin mutation. We therefore tested whether the effect of Gba1b on mitochondrial proteostasis would also correlate with the effect of parkin. However, we detected no significant correlation between Gba1b and parkin effects on mitochondrial protein turnover (Fig 3B) or abundance ( Fig 3C) . Our findings therefore do not support either globally impaired autophagy or selectively impaired mitophagy in Gba1b mutants.
Gba1b mutants have no evidence of impairment in other protein degradation systems
The lack of evidence for autophagy failure led us to consider alternative explanations for the accumulation of ubiquitin-positive protein aggregates in Gba1b mutants. We first considered the possibility that these aggregates could arise because of reduced proteasome function, which is known to lead to the formation of large ubiquitin-positive protein aggregates called aggresomes [33] . We tested proteasome activity using fluorescent substrates, and found that all three enzyme activities were normal (Fig 4A) . We also considered the possibility that delivery of substrates to the proteasome might be impaired [34] , and used our proteomic data to determine whether actual proteasome substrates were degraded normally in Gba1b mutants. We identified cytosolic proteasome substrates based on data from Wagner et al.
[35] (S2 Data) and compared turnover and abundance changes in this group of proteins to the changes in all other cytosolic proteins. If proteasomal degradation were impaired, we would expect substrates of the process to have slowed turnover and possibly increased abundance, as we predicted for autophagy impairment. In fact, however, the percentage of proteins with slowed turnover in Gba1b mutants was significantly lower for proteasome substrates than for other cytosolic proteins, and proteasome substrates did not show a greater incidence of increased abundance in Gba1b mutants (Fig 4B) . Together, these results indicate that proteasome dysfunction does not underlie the accumulation of ubiquitin-positive aggregates in Gba1b mutants.
We next examined whether the protein aggregation in Gba1b mutants could be the result of altered endosomal functioning. As Gba1b mutants have markedly increased levels of glucosylceramide (S1 Fig, [8] ) and moderately decreased levels of ceramide (S1 Fig), abnormal membrane composition could compromise functioning of the endosomal system [36, 37] . We therefore tested for impairment of endosomal microautophagy, an Hsc70-4-dependent process that degrades cytosolic proteins with specific targeting sequences ("KFERQ-like motifs") [38] . To test whether microautophagy is impaired in Gba1b mutants, we searched the Drosophila proteome for proteins with KFERQ-like motifs, and compared the effects of Gba1b on cytosolic proteins with and without such motifs. Compared to proteins without KFERQlike motifs, proteins with one or more KFERQ-like motifs did not have an increased incidence of proteins with slower turnover or increased abundance (Fig 4C, S2 Data) . We also tested whether overexpression of Hsc70-4, which has been shown to increase microautophagy in Drosophila [39] , would influence the accumulation of insoluble ubiquitinated protein. However, this manipulation had no effect on the abundance of ubiquitinated protein aggregates (Fig 4D) . We thus found no evidence that impaired endosomal microautophagy is responsible for the accumulation of ubiquitinated protein aggregates in Gba1b mutants.
We then investigated whether Gba1b mutations impaired the functioning of another endosomal degradation pathway, endocytic turnover. Using FlyBase [40] and other annotation resources, we identified typical substrates of this pathway, primarily integral cell membrane proteins (n = 90 in turnover data, 437 in abundance data; S2 Data). We also identified a separate group of "endosomal machinery" proteins, which reside in endosomes or are required for endocytosis (n = 32 in turnover data, 102 in abundance data; S2 Data). We found no evidence that degradation of endocytic turnover substrates was compromised; compared to all other proteins, endocytic turnover substrates did not have a higher frequency of significantly slowed turnover or increased abundance (Fig 5A) . When we examined endosomal machinery, however, we found a higher prevalence of proteins with increased abundance (p < 0.0001 vs. all other proteins by Fisher exact test; Fig 5B) . Thus, Gba1b mutants had no evidence of compromised endocytic turnover, but proteostasis of the endosomal machinery was clearly altered.
Proteostasis of extracellular vesicle proteins is altered in Gba1b mutants
Many endosomal machinery proteins also play roles in the creation and release of extracellular vesicles (EVs), a heterogeneous population of membrane-delimited structures originating from the multivesicular endosome and plasma membrane [41, 42] . EVs transport varied cargoes of protein and nucleic acids from cell to cell and play roles in signaling, waste disposal, and intercellular resource transfer [43] [44] [45] . EVs have also been implicated in the spread of protein aggregates in neurodegenerative disease [41] . Given that Gba1b mutants have altered turnover and abundance of endosomal machinery proteins but not endocytic turnover substrates, we considered the alternative possibility that GCase deficiency influences EV biology. To explore this hypothesis, we first tested whether proteins known to be associated with EVs showed significant alterations in turnover or abundance in Gba1b mutants. We compiled a list of proteins detected in EVs from Drosophila cultured cells [46] [47] [48] [49] ; the resulting list contained 544 nonredundant proteins (S3 Data), 329 of which were found in the Gba1b turnover data and 499 in the abundance data. Compared to all other proteins in the dataset, a smaller percentage of EV-associated proteins had slowed turnover, and a higher percentage had fasterthan-normal turnover (p < 0.0001 by Fisher exact test; Fig 5C) . In addition, a greater proportion of EV proteins had increased abundance in Gba1b mutants (p < 0.0001 by Fisher exact test; Fig 5C) . To confirm that EV-associated proteins had faster turnover and increased abundance in Gba1b mutants, we repeated our analysis using an independent list of EV proteins. We obtained the ExoCarta [47] "top 100" list of proteins most frequently identified in 
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Drosophila orthologs of the ExoCarta "top 100" list of proteins most frequently detected in mammalian EVs (n = 59 for turnover, 83 for abundance). Faster turnover and increased abundance both occurred more frequently in these EV-associated proteins than in all other proteins.
Ã p < 0.0001 by Fisher exact test (turnover) and χ 2 (abundance).
https://doi.org/10.1371/journal.pgen.1007694.g005
mammalian EVs and identified their Drosophila orthologs using DIOPT v6.0 [50] (n = 97; S3 Data). Once again, compared to the rest of the dataset, EV-associated proteins had higher frequencies of faster turnover and increased abundance in Gba1b mutants (Fig 5D) , suggesting that GCase deficiency may cause dysregulation of EV biology.
Changes in EV proteostasis are specific to Gba1b mutants
To test whether faster turnover and increased abundance of EV-associated proteins are specifically associated with Gba1b loss of function, we investigated whether these proteins were also disproportionately affected by other conditions that alter protein turnover. We evaluated the pattern of changes, as we had done for autophagy substrates, by plotting fold change in turnover against fold change in abundance for all EV-associated proteins. In Gba1b mutants, 59% of the datapoints representing EV proteins appeared in the quadrant representing faster turnover and increased abundance ( Fig 6A) ; in Atg7 mutants, only 3% of EV-associated proteins showed the same pattern ( Fig 6B) . We also looked at the pattern of EV proteostasis in other mutants described in our previous work [21] : the mitophagy mutants parkin and PINK1, and the oxidative stress mutant Sod2. Because abundance data for these mutants lacked enough significant changes for analysis, we analyzed turnover only. None of these mutants showed faster turnover of EV proteins (S2 Fig) .
We also investigated whether the EV proteostasis alterations in Gba1b mutants represented a distinctive pathological process or simply an acceleration of normal aging, given that ubiquitinated protein aggregates accumulate with age even in wild-type flies [51] [52] [53] . To do this, we measured protein turnover and abundance in old flies (55 to 60 days at the start of labeling) and young flies (5 days). Old flies had dramatically slower turnover of most proteins (mean fold change in half-life for all proteins 2.46 ± 4.31) and milder changes in protein abundance (both increases and decreases; S4 Data). In old flies, only 4% of EV-associated proteins were represented by datapoints in the faster turnover/increased abundance quadrant (Fig 6C) , indicating that the altered EV proteostasis observed in Gba1b mutants does not represent an acceleration of normal aging. Together, our findings indicate that altered proteostasis of EVassociated proteins is a specific and novel feature of Gba1b mutants. 
EV-associated proteins are more abundant in EVs from Gba1b mutants
As mentioned above, all of our proteomic analyses were performed using protein extracts from fly heads. To test whether the observed alterations in EV protein abundance were also evident in EVs themselves, we performed western blotting for known EV markers on EV fractions from hemolymph, the Drosophila equivalent of blood. To do this, we collected cell-free hemolymph extracts containing the full range of circulating EVs, which we designated total EVs (tEVs). We also prepared extracts containing only EVs under 220 nm in size, which we designated small EVs (sEVs). We then performed western blot analysis on tEVs or sEVs compared to whole-fly homogenate to measure the abundance of two EV marker proteins: Rab11 and an HA-tagged form of ALiX (PDCD6IP) [48, 54] . We also used western blotting to verify EV isolation by the absence of microsomal markers Calnexin (Cnx99A) and Golgin (Golgin84; Fig 7A and 7E) Rab11 and ALiX-HA were significantly increased in abundance in Gba1b mutants vs. controls in both tEVs and sEVs, but not in whole-fly homogenate (Fig 7A-7E) . Although the Rab11 detected in sEVs was 3-5 kDa smaller than in the whole-fly homogenate, this finding is consistent with previous work demonstrating altered molecular weights for several proteins when detected in EVs [56] . A GFP-tagged form of Rab11 also showed increased abundance in sEVs from Gba1b mutants (S3 Fig). The findings using tagged forms of EV proteins are particularly informative because these exogenous proteins were expressed at equivalent overall levels in controls and Gba1b mutants (Fig 7G, S3 Fig) . The increased abundance of these markers in EVs from Gba1b mutants indicates that either more of each marker protein is loaded into each EV, or that Gba1b mutants produce more EVs.
Ref(2)P is present in Drosophila EVs and is more abundant in EVs from
Gba1b mutants
One of the most striking abnormalities in Gba1b mutants is their accumulation of Ref(2)P [9] , the Drosophila p62 ortholog, which was markedly elevated by proteomic measurement (S1 Data). This is especially noteworthy given that accumulation of Ref(2)P is usually interpreted as an indication of impaired autophagic flux [57] [58] [59] , and yet we find no evidence of impaired autophagic degradation in Gba1b mutants. Ref(2)P/p62 has multiple functions, however, and mammalian p62 has been detected in EVs [47, 60] . We therefore performed western blotting for Ref(2)P on sEVs from Gba1b mutants and controls to test whether Ref(2)P accumulates in EVs. The sEVs contained very little monomeric Ref(2)P, but did reveal a marked increase in higher molecular weight Ref(2)P oligomers (Fig 8A-8C ), which were approximately three times as abundant in Gba1b mutants as in controls (Fig 8C) . We confirmed that these high molecular weight bands represented Ref 
Gba1b mutants have markedly increased numbers of EVs
As mentioned above, the increased abundance of multiple EV-associated proteins in Gba1b mutants suggests either that more of each protein is loaded into each EV, or that more EVs are produced. To distinguish these possibilities, we performed nanoparticle tracking analysis on EVs from the hemolymph of Gba1b mutants and controls. For these experiments, we chose to use a 0.65 μm rather than a 0.22 μm filter to retain EVs of as many sizes as possible while still ensuring removal of all cell debris. While the mean size of EVs was comparable in Gba1b Fig 7. EV marker proteins are more abundant in isolated EVs of Gba1b mutants. (A) Whole-fly homogenates and total extracellular vesicles (tEVs) from Gba1b mutants and controls were probed with an antibody to Rab11. The blots were also probed with antibodies to microsomal markers Calnexin (Cnx99A) and Golgin (Golgin84) to demonstrate the purity of the EV samples. (B) Quantification of Rab11 in tEVs. Homogenate signal was normalized to Ponceau-S loading; all EV mutants and controls (Fig 9A) , the concentration of EVs was approximately six times higher in the mutants (Fig 9B) . The mean concentrations were 4.55 x 10 11 particles/mL (± 1.87 x 10 11 ) for Gba1b mutants and 7.28 x 10 10 particles/mL (±3.36 x 10 10 ) for controls (p = 0.013 by Student t test). Thus, the increased abundance of EV proteins in Gba1b mutants is best explained by the increased production of EVs. Together, our findings give clear evidence of altered EV biology in Gba1b mutants.
Reducing ESCRT-dependent EV release decreases protein aggregation in Gba1b mutants
As previously noted, EVs have been repeatedly described as possible vehicles for the spread of brain protein aggregation in neurodegenerative disease [41] . Our finding that Gba1b mutants had more EVs led us to hypothesize that increased EV release promotes protein aggregation by increasing cell-to-cell transmission of aggregation-prone proteins. As a first step toward testing this model, we determined whether the accumulation of protein aggregates in Gba1b mutants could be suppressed by knocking down components of the ESCRT (endosomal sorting complexes required for transport) pathway, which are required for production of many types of EVs [41, 54] . Using a pan-neuronal driver, we expressed RNAi against proteins from three of the four ESCRT complexes: Mvb12 (Multivesicular body subunit 12; ESCRT-I), lsn (larsen/Vps22; ESCRT-II), and CHMP2B (Charged multivesicular body protein 2b; ESCRT-III). We found that knockdown of each of the three ESCRT proteins significantly reduced accumulation of Ref(2)P in Gba1b mutants, and that knockdown of Mvb12 and lsn also reduced the accumulation of insoluble ubiquitinated protein (Fig 10A-10F) . These findings support the model that excessive production of EVs is responsible for the accumulation of protein aggregates caused by GCase deficiency.
Discussion
Impairment of autolysosomal degradation is widely thought to explain the increased risk of neurodegeneration associated with mutations in GBA, which encodes the lysosomal enzyme glucocerebrosidase (GCase) [1, 16] , and multiple studies have found hallmarks of impaired autophagy associated with GCase loss of function. These hallmarks have included accumulation of ubiquitinated protein aggregates, increased abundance of autophagic flux markers such as p62/SQSTM1 and LC3-II, impairment of autophagosome-lysosome fusion, and changes in the size and number of autophagosomes and lysosomes [12, 13, [61] [62] [63] [64] [65] [66] . These indications that GCase deficiency leads to autophagy impairment have been found in diverse experimental systems, including multiple animal models, cultured cells, iPSC-derived human neuronal models, and postmortem patient samples [8, 11-13, 31, 66-70] . Our own initial characterization of Drosophila Gba1b mutants, which revealed extensive ubiquitinated protein aggregates and markedly elevated levels of the p62 ortholog Ref(2)P, also appeared to support the model that ). Homogenates were prepared from fly heads using 1% Triton X-100. Western blot analysis was performed on the Triton X-100-insoluble proteins using antibodies to ubiquitin (Ub) and Actin, and on the soluble fractions using antibodies to Ref (2) GCase deficiency impairs autophagic degradation [9] . In our current work, however, proteomic measurement of protein turnover and abundance showed no evidence that degradation of autophagy substrates was globally impaired in Gba1b mutants. The mutants also showed no evidence of failure in other protein degradation pathways. Instead, we found faster turnover and increased abundance of proteins associated with extracellular vesicles (EVs). Followup experiments on isolated EVs confirmed increased abundance of EV marker proteins and revealed a strikingly increased number of EVs. Furthermore, genetic manipulations that reduced EV formation suppressed both the increased protein aggregation and the increased Ref(2)P abundance observed in Gba1b mutants. Our findings suggest that dysregulation of extracellular vesicles, rather than failure of autophagic degradation, may be the primary mechanism by which GCase deficiency leads to protein aggregation and neurodegeneration. Although the many previous reports of autophagy impairment in GCase-deficient organisms appear incompatible with our current protein turnover findings, we do not believe that our findings contradict previous work. When we measure common markers of autolysosomal function such as Ref (2)P/p62 and insoluble ubiquitinated protein, Drosophila Gba1b mutants show results comparable to those seen in vertebrate models of GCase deficiency [10, 15, 68, 69, 71] . Our proteomic measurements of protein abundance are also consistent with previous reports of increased lysosomal mass in GCase deficiency [1, 8, 66] . The abundance of the lysosomal marker Lamp1 was nearly tripled in Gba1b mutants, and 41% of lysosomal proteins were significantly increased in abundance (S1 Data). Nevertheless, our protein turnover measurements reveal that the overall rates of degradation through lysosomal processes are not grossly altered. Thus, one possible explanation of our findings is that the efficiency of autolysosomal degradation is decreased, with lower throughput per unit of autolysosomal mass, but that the organism has compensated by increasing the amount of autolysosomal machinery available. Because this compensation is sufficient to maintain degradation rates, we would describe Gba1b mutants as being under autolysosomal stress rather than in autolysosomal failure. Over time, the degree of stress may exceed the capacity to compensate, and aged Gba1b mutants may show overt failure of lysosomal degradation. Even if this is the case, late failure of autolysosomal degradation cannot explain the behavioral and biochemical abnormalities that begin in early adulthood [8, 9] .
Another explanation for the apparent discrepancy between our findings of normal autophagic substrate turnover and previous reports of impaired autophagy is that commonly used autophagy markers are not solely representative of autophagic flux [57, 72] . This is especially true of Ref (2)P, or p62, which has multiple nonautophagic functions and is transcriptionally upregulated by stress [57, 73] . In addition, p62 and LC3 have recently been detected in mammalian EVs [47, 74, 75] , and we found increased levels of oligomeric Ref(2)P in EVs from Gba1b mutants (Fig 8) . It is therefore possible that the increased Ref(2)P levels detected in Gba1b mutants result from a combination of stress response and EV dysregulation.
Our work leaves unanswered the question of how GCase deficiency results in increased EV abundance, but does suggest two possible explanations. Increased production of EVs could be caused either by lysosomal stress or by changes in membrane lipid composition. Lysosomal stress has been shown in cultured cells to promote the release of exosomes, a major type of EV [75, 76] . Exosomes are generated when a multivesicular endosome (MVE) fuses with the plasma membrane rather than the lysosome, releasing its intraluminal vesicles into extracellular space [41, 54] . Lysosomal blockade increases the probability that an MVE will fuse with the plasma membrane [75, 76] . If lysosomal stress rather than outright failure is sufficient to trigger increased exosome release, it could account for the overabundance of EVs in Gba1b mutants.
A second explanation for increased EVs in GCase-deficient animals is that abnormal membrane lipid composition may directly alter EV biogenesis. Lipid composition determines membrane fluidity and curvature, and thus controls the size, shape, and fusion kinetics of EVs [77] [78] [79] . In fact, lipid rafts, particularly those enriched in ceramide, are required for formation at least one type of EV [78] . Membrane changes such as those caused by GCase deficiency, including accumulation of glucosylceramide and altered ceramide levels [80, 81] , could alter EV functioning at any stage from formation to internalization by a recipient cell. Either increased or decreased probability of ceramide-dependent EV formation could lead to increased overall EV production, as suppression of one type of EV has been shown to cause overproduction of another type [82] .
While understanding the mechanism by which GCase deficiency causes increased EV release is an important goal of future work, an equally important question is how increased EV abundance in Gba1b mutants promotes the accumulation of protein aggregates. EVs have been increasingly implicated in the pathogenesis of neurodegenerative disease. Many diseaseassociated proteins, including prion protein, α-synuclein, β-amyloid, and tau, are detected in EVs [41, 83, 84] , which have been proposed as vehicles for the well-documented progressive spread of protein aggregates from one brain region to another [83, 85, 86] . In support of this model, toxic forms of these disease-associated proteins are more abundant in EVs from humans with neurodegenerative diseases such as Alzheimer disease, dementia with Lewy bodies, and Parkinson disease (PD) [84, 87, 88] , and EVs from these patients can induce protein aggregation in recipient cells under experimental conditions [89, 90] . However, progression of these diseases has not yet been conclusively demonstrated to be mediated by EVs. Perhaps the strongest evidence that EVs promote the spread of protein aggregates has been found for prion protein. Stimulating the release of EVs increased the cell-to-cell spread of misfolded prion protein, and decreasing EV release reduced the spread [91] . Our findings appear to follow the same pattern: genetic interference with EV production suppressed protein aggregation in Gba1b mutants. If the same holds true for other aggregation-prone proteins, conditions that increase EV release could promote the spread of protein aggregates and thus be risk factors for neurodegenerative disease.
Fig 11 illustrates this model. When GCase activity is normal (Fig 11A) , EVs travel between cells, carrying both factors that promote protein aggregation (e.g., disease-associated proteins such as α-synuclein) [88, 92] and factors that oppose it (e.g., chaperones) [93] . Some cells likely generate more aggregates than others, and may therefore release more aggregate-promoting factors, including small aggregate "seeds." Quality control mechanisms in recipient cells successfully combat protein aggregation, and aggregates accumulate only slowly with age. If GCase activity is absent or reduced, however (Fig 11B) , more EVs are generated; this results in greater cell-to-cell transfer of aggregate-prone proteins, perhaps simply because these proteins are normally part of EV cargo. In particular, they may be normal cargo of ESCRT-dependent EVs, given our finding that knockdown of ESCRTs in Gba1b mutants ameliorated the mutants' protein aggregation phenotype. Alternatively, GCase deficiency may alter cargo selection so that more aggregation-prone proteins are loaded into EVs. The net effect of the EV changes is transfer of aggregation-producing factors in quantities that overwhelm quality control mechanisms, leading to excessive accumulation of ubiquitin-protein aggregates in recipient cells.
GBA mutations are the strongest single risk factor for PD and dementia with Lewy bodies, affecting up to 10% of PD patients worldwide [2, 5] . Our finding that GCase deficiency causes increased EV release offers new insight into these prevalent disorders. For example, increased transmission of protein aggregates via EVs could explain the earlier onset and faster disease progression in PD patients with GBA mutations [6, [94] [95] [96] [97] . Future investigations should determine how glucocerebrosidase deficiency increases EV abundance, and how manipulations of EV production might prevent or delay the progression of neurodegenerative disease.
Materials and methods
Drosophila strains and culture
Fly stocks were maintained on standard cornmeal-molasses food at 25˚C. The Gba1b null (Gba1b 
Targeted lipidomics
Lipidomic analysis was performed at the Northwest Metabolomics Research Center at the University of Washington, Heads were isolated from 10-day-old control and Gba1b flies flash-frozen in liquid nitrogen, and lipids were then extracted from the frozen head tissue. Levels of glucosylceramide and ceramide were measured by a high-performance liquid chromatography/mass spectrometry (LC-MS/MS) method, using a sphingolipids mix as internal standard (Avanti Sphingolipids Mix II LM-6005). Results were expressed as lipid levels per mass of starting tissue. For each lipid species, three independent samples were analyzed.
Preparation of labeled food [5,5,5 -2 H 3 ] leucine (D3-leucine; 99 atom % deuterium) was obtained from Isotec/SigmaAldrich. Synthetic complete medium without leucine (C-Leu) was supplemented with glucose and 60 mg/L D3-leucine. A strain of Saccharomyces cerevisiae auxotrophic for leucine (BB14-3A, Brewer Lab, University of Washington [103] ) was grown to saturation at 30˚C, then spun down, flash-frozen in liquid nitrogen, lyophilized, and stored at −80˚C.
Because brewing in-house produced limited quantities of labeled yeast, we made labeled fly food in batches of~40 mL using a microwave. We did this by substituting cornstarch for cornmeal in the lab's standard recipe (2.35% yeast w/v) and dispensing the cooked food in small amounts into vials lined with wet Whatman paper to maintain moisture. Unlabeled transition food for the first 24 hours after eclosion was made and dispensed in the same way, substituting Red Star yeast.
In vivo stable isotope labeling of flies
Atg7, parkin, PINK1, and Sod2. These mutants and their controls were labeled using D3-leucine yeast paste as previously described [21] .
Gba1b. 
Mass spectrometry sample preparation
Gba1b and old vs. young studies. Frozen flies were vortexed to remove heads, and the isolated heads were homogenized in 0.1% RapiGest solution in 50 mM ammonium bicarbonate (Waters Corporation, 186001861) using a 0.2-mL Wheaton micro tissue grinder (Fisher Scientific, 08-414-15B). Homogenates were centrifuged at 4˚C at 1600 x g for 10 min, and then at 6500 x g for 10 min, to remove debris and nuclei. The supernatants were then incubated with DTT (final concentration 5 mM) at 60˚C for 30 min. Iodoacetamide was added to a final concentration of 15 mM, and the samples were incubated at room temperature in the dark for 30 min. Trypsin (Fisher Scientific, PR-V5111) was added at a ratio of 1 μg trypsin per 50 μg protein, and incubated for 1 h at 37˚C with shaking. RapiGest was hydrolyzed by adding HCl to a final concentration of 200 mM, followed by incubation at 37˚C with shaking for 45 min. The samples were then centrifuged for 10 min at 4˚C at 20,000 x g, and the supernatant was collected.
Atg7, parkin, PINK1, and Sod2. Samples were prepared as described above except that supernatants were boiled 7 min before incubation with DTT.
Liquid chromatography and mass spectrometry
Atg7, parkin, PINK1, and Sod2 mutant samples were processed as previously described [21] . GBA1b and old/young samples were processed as follows: Fused silica microcapillary columns of 75 μm inner diameter (Polymicro Technologies, Phoenix, AZ) were packed in-house by pressure loading 30 cm of Jupiter 90 Å C12 material (Phenomenex). Kasil (PQ Corporation) frit microcapillary column traps of 100 μm inner diameter with a 2-mm Kasil frit were packed with 4 cm of Jupiter 90 Å C12. A retention time calibration mixture (Pierce) was used to assess quality of the column before and during analysis. Three of these quality control runs were analyzed prior to any sample analysis, and another quality control run was performed after every six sample runs. One microgram of each sample digest and 150 femtomoles of the quality control sample were loaded onto the trap and column by the NanoACQUITY UPLC system (Waters Corporation). Buffer solutions used were water, 0.1% formic acid (buffer A), and acetonitrile, 0.1% formic acid (buffer B). The 60-minute gradient of the quality control consisted of 30 minutes of 98% buffer A and 2% buffer B, 5 minutes of 65% buffer A and 35% buffer B, 10 minutes of 40% buffer A and 60% buffer B, 5 minutes of 95% buffer A and 5% buffer B, and 18 minutes of 98% buffer A and 2% buffer B at a flow rate of 0.3 μL/min. The 240-minute gradient for the sample digest consisted of 120 minutes of 98% buffer A and 2% buffer B, 80 minutes of 65% buffer A and 35% buffer B, 20 minutes of 20% buffer A and 80% buffer B, and 20 minutes of 98% buffer A and 2% buffer B at a flow rate of 0.25 μL/min. Peptides were eluted from the column and electrosprayed directly into an Q-Exactive HF mass spectrometer (Thermo Fisher) with the application of a distal 3 kV spray voltage. For the quality control analysis, a cycle of one 60,000 resolution full-scan mass spectrum (400-1600 m/z) was followed by 17 data-independent MS/MS spectra using an inclusion list at 15,000 resolution, 27% normalized collision energy with a 2 m/z isolation window. For the sample digests, a cycle of one 120,000 resolution full-scan mass spectrum (400-1600 m/z) followed by 20 data-dependent MS/MS spectra on the top 20 most intense precursor ions at 15,000 resolution, 27% normalized collision energy with a 1.5 m/z isolation window. Application of the mass spectrometer and UPLC solvent gradients was controlled by the Thermo Fisher XCalibur data system.
Analysis of mass spectrometry data
The quality control sample data were analyzed using Skyline [23] . High-resolution MS data were processed by BullsEye to optimize precursor mass information [22] . The MS/MS output was searched using COMET [104] with differential modification search of 3.0188325 Da for leucine and 15.994915 methionine and a static modification of 57.021461 Da for cysteine, against a FASTA database containing all the protein sequences from FlyBase plus contaminant proteins. Peptide-spectrum match false discovery rates were determined using Percolator [105] at a threshold of 0.01, and peptides were assembled into protein identifications using an in-house implementation of IDPicker [106] .
Calculation of protein turnover and abundance
Turnover rates were calculated using Topograph software [22] . For a full description of Topograph settings, see Vincow et al. [21] . A protein's turnover rate was computed based on data from all peptides detected, and values from all biological replicates were pooled for turnover calculations. A protein's turnover rate was calculated based on at least 6 measurements per genotype of percent turnover for GBA1b mutants and old/young flies, and at least 15 measurements per genotype for Atg7, parkin, PINK1, or Sod2 mutants. Peptides that could be the product of more than one gene were excluded from analysis. For a small percentage of genes (2%-5%), Topograph clustered peptides corresponding to a single gene into 2-3 nonoverlapping "isoform groups." For example, isoform group 1 might include peptides mapping only to the COX6B-PA isoform, while isoform group 2 peptides could have come from COX6B-PA, -PB, or -PC. While in most cases the isoform groups for a single protein had essentially identical turnover rates, occasionally they displayed significant differences in turnover behavior. Each isoform group was therefore analyzed as a separate protein.
We excluded proteins with excessive inter-replicate variability of turnover rates, defined as coefficient of variation ! 0.25. We calculated the turnover rate separately for each biological replicate and determined the coefficient of variation across replicates. Proteins were analyzed only if they met inclusion criteria in both mutants and controls.
In previous work, we had compared Atg7 and parkin null mutants to their respective heterozygotes [21] . However, we later found that both Atg7 and parkin heterozygotes had mild but significant slowing of mitochondrial protein turnover compared to WT flies, and we selected the WT dataset as a more appropriate control. For turnover analyses, Atg7 and parkin nulls were both compared to a composite WT dataset derived from four separate groups of healthy flies (w
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, PINK1 rv , CyOActGFP/+, and a mixture of'CyO/Hsp70-GAL4 and CyO/ UAS-PINK1#2). Turnover rates are the mean values for all genotypes in which the protein was detected; the rates are highly consistent across genotypes, as previously reported [21] . Each mean value for a genotype was treated as one replicate for statistical purposes. Statistical significance of fold change in turnover was calculated for groups of proteins using nested ANOVA [107] , and significance of change for individual proteins was calculated using t tests. The following subgroups of proteins had enough replicates for t tests: 148 mitochondrial, 36 ribosomal, 15 ER/peroxisomal, and 275 nonorganellar proteins.
We measured protein abundance from the same raw mass spectrometry data used in the turnover study, using Skyline [23] and MSstats [24] . Prior to MSstats analysis, we obtained total abundance (labeled plus unlabeled) for each peptide using a custom R script. The statistical significance of intergroup differences was calculated using a linear mixed model, then adjusted for multiple comparisons by the Benjamini-Hochberg procedure with a false discovery rate of 0.05. All abundance comparisons were made at the second time point, when differences between genotypes were most marked. In abundance analyses, parkin and Atg7 mutants were compared to their original heterozygote controls rather than WT flies (see calculations above). While the composite control group approach was appropriate for measurement of turnover, which is more consistent and less noisy than abundance [21] , measurement of relative protein abundance required mutant and control samples that had been run at the same time.
Annotation and classification of Drosophila proteins
General: Drosophila protein localization was determined from a variety of resources including gene and protein information databases (FlyBase [108] , MitoDrome [109] , NCBI [110] , UniProt [111] ), protein localization prediction algorithms (WoLF PSORT [112] , MitoProt [113] , Predotar [114] , SignalP [115] , NucPred [116] , and PTS1 Predictor [117, 118] ), BLAST [119] , and primary literature.
Proteasome substrates: We identified proteins as proteasome substrates (Fig 4) if their mammalian orthologs had one or more regulated ubiquitinated sites according to Wagner et al. [35] . These sites showed altered abundance of ubiquitinated peptides after proteasome inhibitor treatment. We identified Drosophila orthologs of proteins from the Wagner et al. data with the DRSC Integrative Ortholog Prediction Tool (DIOPT) v6 [50], minimum score 5.
Microautophagy substrates: We identified microautophagy substrates by searching for targeting sequences (Fig 4) , also called KFERQ-like motifs. These motifs were defined as sequences of five amino acids (AAs) that fit criteria established by Dice [120, 121] We wrote an algorithm using Python 2.7 to search protein sequences for these motifs and applied it to the fly proteome (FASTA sequences downloaded from FlyBase). We then identified cytosolic proteins by annotation as described above, and compared the effects of GCase deficiency on cytosolic proteins with and without KFERQ-like sequences. The list contained 544 unique proteins, 329 of which were found in Gba1b mutant protein turnover data and 499 in abundance data. In addition, we obtained from ExoCarta [47] the list of "top 100 [mammalian] proteins that are often identified in exosomes," and identified 97 Drosophila orthologs of these proteins using DIOPT v6 as previously described [50] . Fifty-nine proteins from this list were found in Gba1b mutant turnover data and 86 in abundance data.
The significance of intergroup differences was evaluated using the Fisher exact test except when the total number of proteins was too large, in which case we performed a χ 2 test of homogeneity.
Proteasome enzyme activity assay
Proteasome activity was measured in heads from male and female flies 10 to 11 days old (50 per sample) according to the method of Tsakiri et al. [122] , with the following modifications:
We used 26S lysis buffer only. We obtained substrate buffer and fluorescent substrates from the UBPBio Proteasome Activity Fluorometric Assay Kit II (J4120), and we used epoxomicin 20 μM for proteasome inhibition. Specifically, we divided the lysate in half and added DMSO to one half and epoxomicin to the other. We measured the protein concentration of lysates using the Pierce BCA Protein Assay Kit (23227), and measured sample fluorescence with a Synergy H1 BioTek plate reader (excitation 350 nm, emission 450 nm). We subtracted the activity measured in the epoxomicin-treated homogenate from the activity in the DMSOtreated homogenate. The experiment was repeated three times.
Extraction of hemolymph and preparation of EV fractions
For total EVs (tEVs), hemolymph was obtained from 20 flies (10 males and 10 females, 10 to 11 days old) per sample. In order to obtain whole-fly homogenate from the same animals used for collection of hemolymph, hemolymph was extracted manually from the first four flies and their bodies were reserved for later use. These flies were decapitated, following which their hemolymph was collected by pressing on the thorax with the head of a butterfly pin. The hemolymph from these four flies was collected by capillary action into 1 μL PBS, and the total sample was transferred to a 1.7-mL microfuge tube containing 9 μL PBS. The heads and bodies of the four flies were then homogenized in RIPA buffer for whole-fly protein homogenates. Two holes were made with a 25-g needle in the bottom of a 0.5-mL tube, and 16 more flies were decapitated and placed in this tube. The 0.5-mL tube was then seated in the PBS-containing 1.7-mL tube for centrifugation. The tubes were centrifuged at 5000 x g for 5 min at 4˚C, after which the extracted hemolymph was centrifuged for 30 min at 10,000 x g at 4˚C to remove cell debris and the cell-free supernatant was collected. An equal volume of 2x Laemmli buffer (4% SDS, 20% glycerol, 120 mM Tris-Cl pH 6.8, 0.02% bromophenol blue, 2% β-mercaptoethanol) was added to the cell-free supernatant and also to the whole-fly protein homogenates, and all samples were boiled for 10 min and then stored at −80˚C. The experiment was repeated at least three times. Small EVs (sEVs) were prepared as for tEVs, with the following changes: 50-60 adult flies were used per sample. The hemolymph was collected into a volume of PBS scaled to the number of flies used (1 μL/fly) to minimize sample loss during filtration. After the 10,000 x g spin, Total Exosome Isolation Reagent for Cell Culture (Thermo Fisher/Invitrogen, 4478359) was used as in Tassetto et al. [123] except that we used Ultrafree 0.22 μm spin filters (Fisher, UFC30GV0S). The resulting filtrate was boiled and stored as for the tEVs.
Preparation of Triton-soluble and insoluble fractions
Heads from 10-day-old flies (6 females and 6 males per sample) were homogenized in Triton lysis buffer (50 mM Tris-HCl pH 7.4, 1% Triton X-100, 150 mM NaCl, 1 mM EDTA), and then spun at 15,000 x g for 20 min. The detergent-soluble supernatant was collected and mixed with an equal volume of 2x Laemmli buffer, and the same buffer was used to resuspend the Triton-insoluble pellet. All samples were boiled for 10 minutes. The Triton-insoluble protein extracts were then cleared of debris by centrifugation at 15,000 x g for 10 minutes, followed by collection of the supernatant. At least three independent experiments were performed.
Western blotting
Proteins were separated by SDS-PAGE on 4%-20% MOPS-acrylamide gels (GenScript Express Plus, M42012) and electrophoretically transferred onto Immobilon PVDF membranes (Fisher, IPVH00010). Immunodetection was performed using the iBind Flex Western Device (Thermo Fisher, SLF2000). Antibodies were used at the following concentrations: 1:25,000 mouse antiActin (Chemicon/Bioscience Research Reagents, MAB1501), 1:250 mouse anti-Rab11 (BD Transduction Laboratories, 610657), 1:200 rabbit anti-Ref(2)P (Abcam, ab178440), 1:500 mouse anti-ubiquitin (Santa Cruz, sc-8017), 1:800 mouse anti-Cnx99A (DHSB, Cnx99A 6-2-1), 1:100 mouse anti-Golgin-84 (DHSB, Golgin84 12-1), and 1:500 rat anti-HA (SigmaAldrich, 11867423001). HRP secondary antibodies were used as follows: 1:500 to 1:1000 antimouse (BioRad, 170-6516), 1:100 anti-rat (Sigma-Aldrich, A9037), and 1:500 to 1:1000 antirabbit (BioRad, 172-1019). Signal was detected using Pierce ECL Western Blotting Substrate (Fisher, 32106). Densitometry measurements of the western blot images were measured blind to genotype and condition using Fiji software [49] . For homogenates, signal was normalized either to Actin or to Ponceau-S [124, 125] . For EVs, signal was normalized to loading volume. Normalized western blot data were log-transformed when necessary to stabilize variance before means were compared using Student t test. Each experiment was performed at least three times.
Nanoparticle tracking analysis
EVs were prepared for nanoparticle tracking analysis (NTA) as described for western blotting through the 10,000 x g step, after which they were passed through a 0.65 μm Ultrafree-MC filter (Fisher, UFC30DV0S) to ensure removal of any remaining cellular debris and stored at −80˚C. Hemolymph was obtained from 60 flies per sample, and four biological replicates per genotype were collected.
EV size and concentration were measured using NTA by Alpha Nano Tech LLC (Research Triangle Park, NC). NTA was performed using a ZetaView instrument equipped with an sCMOS camera and 532 nm laser. Instrument parameters were as follows: temperature setting 23˚C, Max Area 500, Min Area 20, Min Brightness 20. Two cycles of analysis at 11 positions were performed for each sample. Data were analyzed using ZetaView software version 8.04.02.
Standard laboratory protection equipment was used during all steps of sample preparation and analysis to prevent sample contamination with dust particles. The 1x PBS solution (Amresco) used to dilute samples was filtered on the day of analysis through a 0.22 μm Millex-GV syringe filter (Millipore), and its purity was confirmed by NTA analysis prior to the study. Instrument qualification was performed by analyzing a polystyrene bead standard (100 nm, Particle Metrix) in 1x PBS prior to each study. Instrument accuracy and precision were confirmed to ± 5% of the target value. 
